Neoadjuvant chemotherapy for "triple Negative" breast cancer: A review of current practice and future outlook

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 531-539

  Nahleh, Zeina ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Chemotherapy; Neoadjuvant; Targeted; Triple negative

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PREDNISOLONE; TAMOXIFEN; TAXANE DERIVATIVE; THIOTEPA; VINCRISTINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CHEMOSENSITIVITY; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; KAPLAN MEIER METHOD; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; NEUROPATHY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; THROMBOPHLEBITIS; TRIPLE NEGATIVE BREAST CANCER;

EID: 77956919796     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9244-6     Document Type: Review

References (62)

1. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-9.
2. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-85.
3. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24:1037-44. doi:10.1200/JCO.2005. 02.6914. (Pubitemid 46638799)
4. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940-9. doi:10.1200/JCO.2005. 02.6187.
5. Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F. Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. Biomed Pharmacother. 2005;59(Suppl 2):S387-92. doi:10.1016/S0753- 3322(05)80085-X.
6. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemoT in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.
7. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019-27. doi:10.1200/JCO.2005.04.1665. (Pubitemid 46622110)
8. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-34. doi:10.1158/1078-0432.CCR-06-1109. (Pubitemid 46698581)
9. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-81. doi:10.1200/JCO. 2007.14.4147.
10. Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004;96:1659-68.
11. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumors. Curr Opin Pharmacol. 2005;5:388-93. doi: 10.1016/j.coph.2005.03.006. (Pubitemid 40932041)
12. Smith IE, A'Hern RP, Coombes GA, et al. A novel continuous infusional 5-fluorouracil-based chemoT regimen compared with conventional chemoT in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol. 2004;15:751-8. doi:10.1093/annonc/mdh175. (Pubitemid 38714736)
13. Chua S, Smith IE, A'Hern RP, et al. Neoadjuvant vinorelbine/ epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol. 2005;16(9):1435-41. doi:10.1093/annonc/mdi276. (Pubitemid 41222415)
14. Pelissier P, Delaloge S, Mathieu MC, et al. Intensified anthracyclin doses do not improve clinical and pathological responses to neoadjuvant FEC for operable breast cancer (BC): results of a multicenter randomized trial [abstract]. Proc Am Soc Clin Oncol. 2002;21:254.
15. Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemoT with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999;17:3412-7.
16. EBCTG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717.
17. Chappuis PO, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet. 2002;39:608-10. doi:10.1136/jmg.39.8.608.
18. Delaloge S. BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts (abstract). Ann Oncol. 2002;13(Suppl 5):34.
19. Guarneri V, Frassoldati A, Giovannelli S, et al. Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives. Cancer Lett. 2007;248:175-85. doi:10.1016/j.canlet. 2006.07.001.
20. de Matteis A, Nuzzo F, D'Aiuto G, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a singlecenter, phase II study. Cancer. 2002;94:895-901. doi:10.1002/ cncr.20335.
21. Espinosa E, Morales S, Borrega P, et al. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemother Pharmacol. 2004;54:546-52. doi:10.1007/s00280-004-0830-1. (Pubitemid 40022251)
22. Wenzel C, Locker GJ, Schmidinger M, et al. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel?granulocyte colony stimulating factor. Anticancer Drugs. 2002;13:67-74. doi:10.1097/ 00001813-200201000-00008.
23. Ganem G, Tubiana-Hulin M, Fumoleau P, et al. Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemoT in patients with operable breast cancer. Ann Oncol. 2003;14:1623-8. doi:10.1093/annonc/mdg449. (Pubitemid 37455810)
24. Gogas H, Papadimitriou C, Kalofonos HP, et al. Neoadjuvant chemoT with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol. 2002;13:1737-42. doi:10.1093/annonc/mdf284. (Pubitemid 35439453)
25. Moliterni A, Tarenzi E, Capri G, et al. Pilot study of primary chemoT with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin Oncol. 1997;24:S17.
26. Bellino R, Cortese P, Danese S, et al. Epidoxorubicin and paclitaxel as primary chemotherapy for T[3 cm and T4 breast cancer patients. Anticancer Res. 2000;20:4825-8.
27. Schneeweiss A, Huober J, Sinn HP, et al. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. Eur J Cancer. 2004;40:2432-8. doi:10.1016/j.ejca.2004.08.004. (Pubitemid 39424957)
28. Conte PF, Donati S, Gennari A, et al. Primary chemoT with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study. Br J Cancer. 2005;93:406-11. doi:10.1038/sj.bjc.6602723. (Pubitemid 43080013)
29. Semlglazov VF, Bojok AA, Arsumanov AS, et al. Breast conserving surgery after neoadjuvant chemoT paclitaxel plus doxorubicin vs fluorouracil plus doxorubicin plus cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2002;76:S52.
30. Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol. 2005;23:2988-95. doi:10.1200/JCO.2005.06. 156. (Pubitemid 46224118)
31. Dieras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol. 2004;22:4958-65. doi:10.1200/JCO. 2004.02.122.
32. Steger GG, Galid A, Gnant M, et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol. 2007;25:2012-8. doi:10.1200/JCO.2006.09.1777. (Pubitemid 46972785)
33. Reitsamer R, Peintinger F, Prokop E, et al. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs. 2005;16:867-70. doi: 10.1097/01.cad.0000173475.59616.b4. (Pubitemid 41215752)
34. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemoT in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456-66. doi:10.1200/JCO.20.6.1456. (Pubitemid 34260523)
35. Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3(Suppl 2):S69-74. doi:10.3816/CBC. 2002.s.015.
36. von MG, Blohmer JU, Raab G, et al. In vivo chemosensitivityadapted preoperative chemoT in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol. 2005;16:56-63. doi:10.1093/annonc/mdi001. (Pubitemid 40124479)
37. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005;23:5983-92. doi:10.1200/JCO.2005.06.232.
38. Hayes DF, Thor AD, Dressler LG, et al. HER2/neu and response to paclitaxel in node-positive breast cancer. Cancer and Leukemia Group B (CALGB) Investigators. N Engl J Med. 2007;357(15): 1496-506. doi:10.1056/NEJMoa071167. (Pubitemid 47572635)
39. Baldini E, Gardin G, Giannessi PG, et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol. 2003;14:227-32. doi:10.1093/annonc/mdg069. (Pubitemid 36305434)
40. Euler U, Dresel V, Buhner M, et al. Dose and time intensified epirubicin/cyclophosphamide (EC) as preoperative treatment in locally advanced breast cancer. Breast Cancer Res Treat. 2002; 76:S51.
41. Miller KD, Caskill-Stevens W, Sisk J, et al. Combination versus sequential doxorubicin and docetaxel as primary chemoT for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol. 1999;17:3033-7.
42. von MG, Costa SD, Eiermann W, et al. Maximized reduction of primary breast tumor size using preoperative chemoT with doxorubicin and docetaxel. J Clin Oncol. 1999;17:1999-2005.
43. Cooper BW, Radivoyevitch T, Overmoyer BA, et al. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. Breast Cancer Res Treat. 2006;97:311-8. doi:10.1007/s10549- 005-9125-4.
44. Untch M, Konency G, Ditsch N, et al. Dose-dense sequential epirubicin-pacilitaxel as preoperative treatment of breast cancer: results of a randomized AGO study [abstract]. Proc Am Soc Clin Oncol. 2002;21:34a.
45. Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676-85. doi:10.1200/JCO.2005.05.078. (Pubitemid 46179457)
46. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431-9. doi:10.1200/JCO. 2003.09.081.
47. Gluz O, Nitz UA, Harbeck N. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. West German Study Group. Ann Oncol. 2008;19(5):861-70. doi: 10.1093/annonc/mdm551. (Pubitemid 351649186)
48. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA crosslinking agent cisplatin. J Biol Chem. 2000;275:23899-903. doi: 10.1074/jbc.C000276200. (Pubitemid 30624678)
49. Garber JE, Richardson A, Harris LN, et al. Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC). Proceedings San Antonio Breast Cancer Symposium, 2006 (Abstract 3074). SABCS 2006 (abstract 3074).
50. Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008;19(11): 1847-52. doi:10.1093/annonc/mdn395.
51. Cleator S, Helle W, Coombes CR. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8(3):235-44.
52. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434(7035):917-21. doi:10.1038/nature03445. (Pubitemid 40559006)
53. Ratnam K, Low JA. Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology. Clin Cancer Res. 2007;13(5):1383-8. doi:10.1158/1078-0432.CCR-06-2260. (Pubitemid 46450426)
54. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triplenegative/ basal-like breast carcinomas. Breast Cancer Res. 2007; 9(5):R65. doi:10.1186/bcr1771. (Pubitemid 350187481)
55. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-52. doi:10.1038/35021093.
56. Van de Vijver MJ, He YD, van't Veer LJ, et al. A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009. doi:10.1056/NEJMoa021967. (Pubitemid 35461656)
57. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemoT in breast cancer. J Clin Oncol. 2004;22:2284-93. doi:10.1200/ JCO.2004.05.166. (Pubitemid 41115384)
58. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362-9. doi: 10.1016/S0140-6736(03)14023-8. (Pubitemid 36957839)
59. Chang JC, Wooten EC, Tsimelzon A, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005;23:1169-77. doi:10.1200/JCO.2005.03.156. (Pubitemid 46202273)
60. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemoT. Clin Cancer Res. 2005;11:5678-85. doi:10.1158/1078-0432.CCR-04-2421. (Pubitemid 41170290)
61. Thuerigen O, Schneeweiss A, Toedt G, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol. 2006;24:1839-45. doi:10.1200/JCO.2005.04.7019. (Pubitemid 46638981)
62. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemoT in women with locally advanced breast cancer. J Clin Oncol. 2005;23:7265-77. doi:10.1200/JCO.2005.02.0818. (Pubitemid 46202341)